
ChromaDex Corp (NAGE) Stock Forecast & Price Target
ChromaDex Corp (NAGE) Analyst Ratings
Bulls say
Niagen Bioscience is a leader in NAD+ science and healthy-aging research, with a strong focus on precision science and innovative NAD+-boosting solutions. The company's recent financial results have shown moderate revenue outperformance, and they have multiple methods to drive future growth, including expanding into new markets and developing new products. The company also has a strong IP portfolio with over 100 patents and potential in multiple industries, including rare diseases. With the increasing global focus on health and wellness, Niagen Bioscience is well-positioned for long-term success.
Bears say
Niagen Bioscience is currently trading at a steep valuation and faces significant risks, including potential slower sales growth, unfavorable clinical data, adverse legal decisions, and geopolitical disruptions. Despite strong projected financials and attractive valuations compared to other supplement companies, recent stock performance and macro volatility suggest caution for potential investors. One-time gains from the sale of a subsidiary and the potential for future revenue from an AT opportunity may provide upside, but it remains to be seen if consumers will continue to prioritize health and wellness products during times of economic uncertainty.
This aggregate rating is based on analysts' research of ChromaDex Corp and is not a guaranteed prediction by Public.com or investment advice.
ChromaDex Corp (NAGE) Analyst Forecast & Price Prediction
Start investing in ChromaDex Corp (NAGE)
Order type
Buy in
Order amount
Est. shares
0 shares